This kind of “dead cell”‐based delivery vehicle can be rapidly manufactured for clinical use compared to live cell‐based drug delivery systems.[133] Recently, the effect of combining cryo‐treatment and immunotherapy was reported.[135] In these basic and clinical studies, CTLA‐4 and PD‐1 antagonists play complementary roles in activating cancer immunity, and cryotherapy after immunotherapy can induce a stronger cancer‐specific immune response to distant lesions. The gene discussed is CTLA4; the disease is cancer.